Name: 글로벌 시장 동향
SKU: PH258
Availability: InStock

보고서 요약(국문)

시장 개요
전 세계 당뇨병성 신경병증 시장은 2022년 37억 7,540만 달러에 달했으며, 2030년까지 62억 9,810만 달러로 성장할 것으로 예상됩니다. 당뇨병성 신경병증 시장은 예측 기간(2023~2030년) 동안 연평균 6.7%의 성장률을 보일 것으로 전망됩니다.
당뇨병성 신경병증은 당뇨병으로 인해 신경이 손상되는 질환으로, 주로 발이나 하퇴부에 통증과 감각 소실을 유발합니다. 신경병증의 영향 범위에 따라 통증은 엉덩이, 손목, 허리 등 신체의 다른 부위에서도 나타날 수 있습니다. 신경병증에는 국소 신경병증, 근위 신경병증, 말초 신경병증, 자율 신경병증 등 다양한 유형이 있습니다.
당뇨병 환자 수와 고령 인구의 증가, 그리고 여러 정부 기관의 자금 지원 확대가 전 세계 당뇨병성 신경병증 시장 성장을 견인하고 있습니다.

시장 동향
증가하는 고령 인구가 예측 기간 동안 전 세계 당뇨병성 신경병증 시장 성장을 견인할 것으로 예상됩니다.
신경병증은 65세 이상에서 매우 흔하며, 나이가 들수록 발병률이 증가합니다. 따라서 고령 인구의 증가는 전 세계 당뇨병성 신경병증 시장 성장을 주도하고 있습니다. 예를 들어, 유엔의 2022년 세계 인구 전망에 따르면 80세 이상 인구는 2022년 1억 5,700만 명에서 2050년 4억 5,900만 명으로 세 배 증가할 것으로 예상됩니다.
다양한 정부 기관의 자금 지원 증가는 전 세계 당뇨병성 신경병증 시장에 유망한 성장 기회를 제공하고 있습니다.
다양한 정부 기관의 자금 지원 확대는 전 세계 당뇨병성 신경병증 시장에 매력적인 성장 기회를 제공하고 있습니다. 예를 들어, 미국 보건복지부는 인디언 보건국을 통해 2023 회계연도 인디언 특별 당뇨병 프로그램(SDPI)에 1억 3,900만 달러를 지원하여 미국령 알래스카와 인디언 원주민 공동체에 당뇨병 예방 및 치료 지원을 제공하고 있습니다.
코로나19 영향 분석
코로나19 분석에는 코로나19 이전 시나리오, 코로나19 기간 시나리오, 코로나19 이후 시나리오와 함께 가격 변동(팬데믹 기간 및 이후의 가격 변화를 코로나19 이전 시나리오와 비교), 수요-공급 양상(거래 제한, 봉쇄 및 그로 인한 문제로 인한 수요와 공급의 변화), 정부 정책(정부 기관의 시장, 부문 또는 산업 활성화 정책), 제조업체의 전략적 정책(제조업체가 코로나19 문제를 완화하기 위해 취한 조치)이 포함됩니다.

러시아-우크라이나 전쟁 영향 분석
현재 우크라이나에서는 만성 질환 환자들이 겪고 있는 문제들이 더욱 악화되고 있습니다. 침공으로 인해 전기, 난방, 깨끗한 물과 같은 기본적인 필수품조차 제대로 공급되지 못하는 상황에서 만성 질환 치료제와 같은 의료 지원이 부족하기 때문입니다. 따라서 러시아-우크라이나 전쟁은 전 세계 당뇨병성 신경병증 시장에 부정적인 영향을 미쳤습니다.
글로벌 경기 침체 영향 분석
의료 산업 역시 경기 침체에 완전히 면역된 것은 아닙니다. 과거 경기 침체기에도 의료 기관들은 인력 감축과 채용을 반복해 왔습니다. 이는 의료 산업이 다른 산업에 비해 상대적으로 잘 대처하고 있음을 의미합니다. 그러나 경기 침체와 인플레이션의 지속은 시장에 위협이 되고 있습니다.
지난 2년간 선진국의 높은 인플레이션과 현재 진행 중인 경기 침체에 대한 압박은 전반적인 물가 상승으로 이어졌습니다.

인공지능(AI) 영향 분석
AI는 방대한 데이터를 처리하고 환자 경험을 종합하여 예측 정보를 제공함으로써 전 세계 당뇨병성 신경병증 시장에 긍정적인 영향을 미칠 것으로 예상됩니다. 이를 통해 의료 생태계는 개선이 필요한 환자 치료의 핵심 요소를 파악할 수 있습니다.
시장 세분화 분석
전 세계 당뇨병성 신경병증 시장은 유형, 약물 종류, 유통 채널 및 지역별로 세분화됩니다.
비스테로이드성 항염증제(NSAIDs) 부문, 전 세계 시장 점유율 35.4% 예상
NSAIDs 부문은 처방전 없이 구입할 수 있어 환자들이 거주지에서 쉽게 구할 수 있기 때문에 전 세계 당뇨병성 신경병증 시장에서 가장 큰 비중을 차지할 것으로 예상됩니다. 또한, 대부분의 NSAIDs는 제네릭 의약품이 시장에 출시되어 가격이 저렴하고 심각한 부작용 없이 빠른 증상 완화를 제공합니다.

지리적 분석
유럽은 예측 기간 동안 전 세계 당뇨병성 신경병증 시장에서 두 번째로 큰 점유율을 차지할 것으로 예상됩니다.
당뇨병 발병률 증가로 인해 유럽은 전 세계 당뇨병성 신경병증 시장의 약 26.3%를 차지할 것으로 예상됩니다. 예를 들어, 세계보건기구(WHO)에 따르면 유럽 지역에는 6천만 명이 넘는 당뇨병 환자가 있으며, 이는 25세 이상 남성의 약 10.3%, 여성의 약 9.6%에 해당합니다. 유럽 지역에서 모든 세대에 걸쳐 당뇨병 발병률이 증가하고 있는데, 이는 주로 과체중 및 비만 증가, 건강에 좋지 않은 음식 섭취, 그리고 신체 활동 부족 때문입니다.
경쟁 환경
시장의 주요 글로벌 기업으로는 Depomed Pharma, Eli Lilly, Daiichi Sankyo, Teva Pharmaceutical Industries Ltd., Xenoport, Grünenthal, Johnson and Johnson, Pfizer, GlaxoSmithKline, Boehringer Ingelheim 등이 있습니다.

보고서 구매 이유

• 유형, 약물 종류, 유통 채널 및 지역별 글로벌 당뇨병성 신경병증 시장 세분화를 시각화하고 주요 상업 자산 및 주요 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴합니다.

• 모든 세그먼트를 포함한 당뇨병성 신경병증 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 포함한 제품 맵핑 자료를 Excel 파일로 제공합니다.

글로벌 당뇨병성 신경병증 시장 보고서는 약 53개의 표, 54개의 그림, 195페이지 분량입니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
The global diabetic neuropathy market reached USD 3,775.4 million in 2022 and is projected to witness lucrative growth by reaching up to USD 6,298.1 million by 2030. The diabetic neuropathy market is expected to exhibit a CAGR of 6.7% during the forecast period (2023-2030).
Diabetic neuropathy is the deterioration induced to the nerve because of diabetes, which usually causes pain and loss of sensation in the feet or lower legs. The pain can be encountered in different body parts like hips, wrists, and back based on the impact of neuropathy. There are different types of neuropathy like focal neuropathy, proximal neuropathy, peripheral neuropathy, and autonomic neuropathy.
The growing number of diabetes patients and the geriatric population, and increasing funding initiatives from various government organizations are driving the global diabetic neuropathy market growth.
Market Dynamics
The Growing Geriatric Population is Expected to Drive The Global Diabetic Neuropathy Market Over The Forecast Period.
Neuropathies are exceptionally typical in individuals over 65 years old and their preponderance upsurges with age. Thus, the growing geriatric population is driving the global diabetic neuropathy market. For instance, according to the World Population Prospects 2022, from the UN, the number of individuals aged 80 or above is anticipated to grow triple fold, from 157 million in 2022 to 459 million by 2050.
The Increasing Funding from Various Government Organizations is Providing the Global Diabetic Neuropathy Market with Prospective Growth Opportunities
The increasing funding initiatives from various government organizations are presenting the global diabetic neuropathy market with lucrative growth opportunities. For instance, the U. S. Department of Health and Human Services, via the Indian Health Service, is funding $139 million for the Fiscal Year 2023 Special Diabetes Program for Indians (SDPI) to deliver diabetes prevention and therapy assistance for American Alaska and Indian Native communities.
COVID-19 Impact Analysis
The COVID-19 analysis includes Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario along with pricing dynamics (including pricing change during and post-pandemic comparing it to pre-COVID scenarios), demand-supply spectrum (shift in demand and supply owing to trading restrictions, lockdown, and subsequent issues), government initiatives (initiatives to revive market, sector or industry by government bodies) and manufacturers strategic initiatives (what manufacturers did to mitigate the COVID issues will be covered here).
Russia-Ukraine War Impact Analysis
The issues that are currently being encountered by individuals with chronic conditions in Ukraine are increased by a deficiency of medical support such as medications for chronic disorders at a time when fundamental requirements like electricity, heating, and clean water are not being attended, to because of the invasion. Thus, the Russia-Ukraine war has negatively impacted the global diabetic neuropathy market.
Global Recession Impact Analysis
The healthcare industry is not completely invulnerable to a recession, as healthcare organizations supposed layoffs and hirings in past financial downturns. That remarked the enterprise does manage better compared to different sectors. Yet, the threat of recession risks the market as inflation succeeds.
The extended degree of stress concerning the ongoing recession as the high inflation in developed countries worldwide has transpired in an all-around price ripple through the past two years.
Artificial Intelligence Impact Analysis
AI is anticipated to hold a positive influence on the global diabetic neuropathy market as with AI's capacity to process big data pools, combining patient experiences can direct to predictive benefits, enabling the healthcare ecosystem to expose key dimensions of patient care that need revision.
Segment Analysis
The global diabetic neuropathy market is segmented based on type, drug class, distribution channel, and region.
The NSAIDS Segment is Estimated To Hold a 35.4% Share of the Global Market
The NSAIDs segment is estimated to hold the largest share of the global diabetic neuropathy market, owing to the easy availability of the NSAIDs as are over the counter and hence, readily available for patients in their residents. Additionally, majority of the NSAIDs have their generic formulations obtainable in the market making them affordable and these drugs deliver quick relief without any severe side effects.
Geographical Analysis
Europe is Estimated to Hold the Second-Largest Share of the Global Diabetic Neuropathy Market During the Forecast Period
Owing to the increasing incidence of diabetes, Europe is estimated to hold about 26.3% of the global diabetic neuropathy market. For instance, according to WHO, there are over 60 million individuals with diabetes in the European region, or nearly 10.3% of males and 9.6% of females aged 25 years and above. The preponderance of diabetes is rising among all generations in the European region, primarily because of the increase in overweight and obesity, unhealthy food consumption, and less physical inactivity.
Competitive Landscape
The major global players in the market include Depomed Pharma, Eli Lilly, Daiichi Sankyo, Teva Pharmaceutical Industries Ltd., Xenoport, Grünenthal, Johnson and Johnson, Pfizer, GlaxoSmithKline, and Boehringer Ingelheim among others.
WHY PURCHASE THE REPORT?
• To visualize the global diabetic neuropathy market segmentation based on type, drug class, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of diabetic neuropathy market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global diabetic neuropathy market report would provide approximately 53 tables, 54 figures, and 195 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Drug Type
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Growing Cases of Diabetes
4.1.1.2. Market Developments
4.1.2. Restraints
4.1.2.1. Stringent Regulatory Authorities
4.1.3. Opportunity
4.1.4. Government Initiatives
4.1.5. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Forces Analysis
5.2. Regulatory Analysis
5.3. Pricing Analysis
5.4. Patent Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Post COVID-19 & Future Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. Russia-Ukraine War Analysis
8. Global Recession Analysis
9. Artificial Intelligence Analysis
10. By Type
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.1.2. Market Attractiveness Index, By Type
10.2. Peripheral Neuropathy
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Autonomic Neuropathy
10.4. Proximal Neuropathy
10.5. Focal Neuropathy
11. By Drug Class
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.1.2. Market Attractiveness Index, By Drug Class
11.2. Anti-Depressant
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Anti-Convulsant
11.4. Opioids
11.5. NSAIDs
11.6. Others
12. By Distribution Channel
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.1.2. Market Attractiveness Index, By Distribution Channel
12.2. Hospitals and Clinics Pharmacy
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Retail Pharmacy and Stores and Stores
12.4. Online Pharmacy
13. By Region
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
13.1.2. Market Attractiveness Index, By Region
13.2. North America
13.2.1. Introduction
13.2.2. Key Region-Specific Dynamics
13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.2.6.1. The U.S.
13.2.6.2. Canada
13.2.6.3. Mexico
13.3. Europe
13.3.1. Introduction
13.3.2. Key Region-Specific Dynamics
13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.3.6.1. Germany
13.3.6.2. The U.K.
13.3.6.3. France
13.3.6.4. Italy
13.3.6.5. Spain
13.3.6.6. Rest of Europe
13.4. South America
13.4.1. Introduction
13.4.2. Key Region-Specific Dynamics
13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.4.6.1. Brazil
13.4.6.2. Argentina
13.4.6.3. Rest of South America
13.5. Asia-Pacific
13.5.1. Introduction
13.5.2. Key Region-Specific Dynamics
13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.5.6.1. China
13.5.6.2. India
13.5.6.3. Japan
13.5.6.4. Australia
13.5.6.5. Rest of Asia-Pacific
13.6. Middle East and Africa
13.6.1. Introduction
13.6.2. Key Region-Specific Dynamics
13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14. Competitive Landscape
14.1. Competitive Scenario
14.2. Market Share Analysis
14.3. Mergers and Acquisitions Analysis
15. Company Profiles
15.1. Depomed Pharma
15.1.1. Company Overview
15.1.2. Type Portfolio and Description
15.1.3. Financial Overview
15.1.4. Key Developments
15.2. Eli Lilly and Company
15.3. Daiichi Sankyo
15.4. Teva Pharmaceutical Industries Ltd.
15.5. Xenoport
15.6. Grünenthal
15.7. Johnson and Johnson
15.8. Pfizer
15.9. GlaxoSmithKline
15.10. Boehringer Ingelheim
LIST NOT EXHAUSTIVE
16. Appendix
16.1. About Us and Services
16.2. Contact Us

언급된 주요 기업들

Depomed Pharma, 4.	Key Developments, Eli Lilly and Company, Daiichi Sankyo, Teva Pharmaceutical Industries Ltd., Xenoport, Grünenthal, Johnson and Johnson, Pfizer, GlaxoSmithKline, Boehringer Ingelheim

표 목록 (Tables)

List of Tables Table 1 Global Diabetic Neuropathy Market Value, By Type, 2025, 2029 & 2033 (US$ Billion)

Table 2 Global Diabetic Neuropathy Market Value, By Drug Class, 2025, 2029 & 2033 (US$ Billion)

Table 3 Global Diabetic Neuropathy Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)

Table 4 Global Diabetic Neuropathy Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)

Table 5 Global Diabetic Neuropathy Market Value, By Type, 2025, 2029 & 2033 (US$ Billion)

Table 6 Global Diabetic Neuropathy Market Value, By Type, 2022-2033 (US$ Billion)

Table 7 Global Diabetic Neuropathy Market Value, By Drug Class, 2025, 2029 & 2033 (US$ Billion)

Table 8 Global Diabetic Neuropathy Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 9 Global Diabetic Neuropathy Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)

Table 10 Global Diabetic Neuropathy Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 11 Global Diabetic Neuropathy Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)

Table 12 Global Diabetic Neuropathy Market Value, By Region, 2022-2033 (US$ Billion)

Table 13 North America Diabetic Neuropathy Market Value, By Type, 2022-2033 (US$ Billion)

Table 14 North America Diabetic Neuropathy Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 15 North America Diabetic Neuropathy Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 16 North America Diabetic Neuropathy Market Value, By Country, 2022-2033 (US$ Billion)

Table 17 Europe Diabetic Neuropathy Market Value, By Type, 2022-2033 (US$ Billion)

Table 18 Europe Diabetic Neuropathy Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 19 Europe Diabetic Neuropathy Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 20 Europe Diabetic Neuropathy Market Value, By Country, 2022-2033 (US$ Billion)

Table 21 Asia-Pacific Diabetic Neuropathy Market Value, By Type, 2022-2033 (US$ Billion)

Table 22 Asia-Pacific Diabetic Neuropathy Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 23 Asia-Pacific Diabetic Neuropathy Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 24 Asia-Pacific Diabetic Neuropathy Market Value, By Country, 2022-2033 (US$ Billion)

Table 25 South America Diabetic Neuropathy Market Value, By Type, 2022-2033 (US$ Billion)

Table 26 South America Diabetic Neuropathy Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 27 South America Diabetic Neuropathy Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 28 South America Diabetic Neuropathy Market Value, By Country, 2022-2033 (US$ Billion)

Table 29 Middle East and Africa Diabetic Neuropathy Market Value, By Type, 2022-2033 (US$ Billion)

Table 30 Middle East and Africa Diabetic Neuropathy Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 31 Middle East and Africa Diabetic Neuropathy Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 32 Middle East and Africa Diabetic Neuropathy Market Value, By Country, 2022-2033 (US$ Billion)

Table 33 Eli Lilly and Company: Overview

Table 34 Eli Lilly and Company: Product Portfolio

Table 35 Eli Lilly and Company: Key Developments

Table 36 Pfizer Inc.: Overview

Table 37 Pfizer Inc.: Product Portfolio

Table 38 Pfizer Inc.: Key Developments

Table 39 Collegium Pharmaceutical, Inc: Overview

Table 40 Collegium Pharmaceutical, Inc: Product Portfolio

Table 41 Collegium Pharmaceutical, Inc: Key Developments

Table 42 Lupin Pharmaceuticals: Overview

Table 43 Lupin Pharmaceuticals: Product Portfolio

Table 44 Lupin Pharmaceuticals: Key Developments

Table 45 Averitas Pharma, Inc: Overview

Table 46 Averitas Pharma, Inc: Product Portfolio

Table 47 Averitas Pharma, Inc: Key Developments

Table 48 Daiichi Sankyo: Overview

Table 49 Daiichi Sankyo: Product Portfolio

Table 50 Daiichi Sankyo: Key Developments

그림 목록 (Figures)

List of Figures Figure 1 Global Diabetic Neuropathy Market Value, 2022-2033 (US$ Billion)

Figure 2 Global Diabetic Neuropathy Market Share, By Type, 2024 & 2033 (%)

Figure 3 Global Diabetic Neuropathy Market Share, By Drug Class, 2024 & 2033 (%)

Figure 4 Global Diabetic Neuropathy Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 5 Global Diabetic Neuropathy Market Share, By Region, 2024 & 2033 (%)

Figure 6 Global Diabetic Neuropathy Market Y-o-Y Growth, By Type, 2023-2033 (%)

Figure 7 Peripheral Diabetic Neuropathy Market Value, 2022-2033 (US$ Billion)

Figure 8 Autonomic Diabetic Neuropathy Market Value, 2022-2033 (US$ Billion)

Figure 9 Proximal Diabetic Neuropathy Market Value, 2022-2033 (US$ Billion)

Figure 10 Focal Diabetic Neuropathy Market Value, 2022-2033 (US$ Billion)

Figure 11 Global Diabetic Neuropathy Market Y-o-Y Growth, By Drug Class, 2023-2033 (%)

Figure 12 Anti-Depressants Drug Class in Global Diabetic Neuropathy Market Value, 2022-2033 (US$ Billion)

Figure 13 Non-Steroidal Anti-Inflammatory Drugs Drug Class in Global Diabetic Neuropathy Market Value, 2022-2033 (US$ Billion)

Figure 14 Opioid Drug Class in Global Diabetic Neuropathy Market Value, 2022-2033 (US$ Billion)

Figure 15 Anti-Seizure Drug Class in Global Diabetic Neuropathy Market Value, 2022-2033 (US$ Billion)

Figure 16 Others Drug Class in Global Diabetic Neuropathy Market Value, 2022-2033 (US$ Billion)

Figure 17 Global Diabetic Neuropathy Market Y-o-Y Growth, By Distribution Channel, 2023-2033 (%)

Figure 18 Hospital Pharmacies Distribution Channel in Global Diabetic Neuropathy Market Value, 2022-2033 (US$ Billion)

Figure 19 Retail Pharmacies Distribution Channel in Global Diabetic Neuropathy Market Value, 2022-2033 (US$ Billion)

Figure 20 Online Pharmacies Distribution Channel in Global Diabetic Neuropathy Market Value, 2022-2033 (US$ Billion)

Figure 21 Global Diabetic Neuropathy Market Y-o-Y Growth, By Region, 2023-2033 (%)

Figure 22 North America Diabetic Neuropathy Market Value, 2022-2033 (US$ Billion)

Figure 23 North America Diabetic Neuropathy Market Share, By Type, 2024 & 2033 (%)

Figure 24 North America Diabetic Neuropathy Market Share, By Drug Class, 2024 & 2033 (%)

Figure 25 North America Diabetic Neuropathy Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 26 North America Diabetic Neuropathy Market Share, By Country, 2024 & 2033 (%)

Figure 27 Europe Diabetic Neuropathy Market Value, 2022-2033 (US$ Billion)

Figure 28 Europe Diabetic Neuropathy Market Share, By Type, 2024 & 2033 (%)

Figure 29 Europe Diabetic Neuropathy Market Share, By Drug Class, 2024 & 2033 (%)

Figure 30 Europe Diabetic Neuropathy Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 31 Europe Diabetic Neuropathy Market Share, By Country, 2024 & 2033 (%)

Figure 32 Asia-Pacific Diabetic Neuropathy Market Value, 2022-2033 (US$ Billion)

Figure 33 Asia-Pacific Diabetic Neuropathy Market Share, By Type, 2024 & 2033 (%)

Figure 34 Asia-Pacific Diabetic Neuropathy Market Share, By Drug Class, 2024 & 2033 (%)

Figure 35 Asia-Pacific Diabetic Neuropathy Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 36 Asia-Pacific Diabetic Neuropathy Market Share, By Country, 2024 & 2033 (%)

Figure 37 South America Diabetic Neuropathy Market Value, 2022-2033 (US$ Billion)

Figure 38 South America Diabetic Neuropathy Market Share, By Type, 2024 & 2033 (%)

Figure 39 South America Diabetic Neuropathy Market Share, By Drug Class, 2024 & 2033 (%)

Figure 40 South America Diabetic Neuropathy Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 41 South America Diabetic Neuropathy Market Share, By Country, 2024 & 2033 (%)

Figure 42 Middle East and Africa Diabetic Neuropathy Market Value, 2022-2033 (US$ Billion)

Figure 43 Middle East and Africa Diabetic Neuropathy Market Share, By Type, 2024 & 2033 (%)

Figure 44 Middle East and Africa Diabetic Neuropathy Market Share, By Drug Class, 2024 & 2033 (%)

Figure 45 Middle East and Africa Diabetic Neuropathy Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 46 Eli Lilly and Company: Financials

Figure 47 Pfizer Inc.: Financials

Figure 48 Collegium Pharmaceutical, Inc: Financials

Figure 49 Lupin Pharmaceuticals: Financials

Figure 50 Averitas Pharma, Inc: Financials

Figure 51 Daiichi Sankyo: Financials

세계 당뇨병성 신경병증 시장 – 2023-2030

Global Diabetic Neuropathy Market - 2023-2030